Factsheet and Information Brochure
Factsheet
Target Market
Costs and charges
Fund rules (175 kB)
Prospectus (1373 kB)
Periodic reports
Sustainability SFDR (995 kB)
Annual review (PF) (3106 kB)
Semi-annual report (PF) (199 kB)
Marketing material
Sustainability profile
Brief fund information
Summary SFDR (171 kB)
Pre-contractual SFDR
Pre-contractual SFDR (894 kB)
Handelsbanken Hälsovård Tema (A10 EUR)
Legal name: Handelsbanken Hälsovård Tema (A10 EUR)
Equity Fund Registered in Sweden (UCITS)
Bid
About risk
Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.
The fund is actively managed and invests globally in equities issued by companies within the healthcare sector. As a result, the fund has a currency exposure to these markets. The healthcare sector refers to the pharmaceutical, medical technology, biotech, service and other healthcare-related branches.
The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time.
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 9 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
The thematic investment strategy provides for investments that occur in a limited area in which development is deemed to result in a structural change to the economy and society. This change provides favorable conditions for companies active within the area to create profitable growth over time.
For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.
The fund is reported as an Article 9 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Fund Spotlight
The fund rules will be changed on 10 October 2025.Read more
Fund manager
Christopher Sundman Experience in the fund industry 1987. Portfolio Manager since 1 August 2022.
Fund manager
Caroline Banér Experience in the fund industry 2009. Portfolio Manager since 1 October 2024.
|
|
||
|---|---|---|---|
|
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
|
|
30.09.2025
|
||
|---|---|---|---|
|
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating |
|
|
||
|---|---|---|---|
|
The fund has sustainable investments as its objective. Accordingly, the fund invests in companies with products and services that are considered as contributing positively to the direct fulfillment of one or several of the targets in Agenda 2030. Refer to the fund's prospectus for additional information. The fund is reported as an Article 9 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR). Read more |
|
31.07.2025
|
|||
|---|---|---|---|
|
The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating. The fund complies with the UN Principles for Responsible Investments. |
Graph
Performance
| Rate 13.10.2025 | 1 week | 1 month | 3 months | 2025 | 1 year | 5 years | 10 years |
|---|---|---|---|---|---|---|---|
| 39.62 EUR | -0.33% | 5.60% | 9.81% | -3.34% | -9.89% | - | - |
Portfolio 09.10.2025
Portfolio manager comments — Q3 2025
The quarter was marked by uncertainty surrounding the final U.S. tariffs and how the so called MFN principle (Most Favoured Nations – stipulating that prices in the U.S. must not exceed those in selected reference countries) will be applied. The fund gained approximately 3.9% in SEK, outperforming its benchmark, the Solactive ISS ESG Screened DM Health Care Index NTR, by nearly 2%.
At the very end of the quarter, the Trump administration reached an agreement with Pfizer, which is expected to serve as a potential blueprint for the entire pharmaceutical sector. This triggered a relief rally within the sector, which had previously underperformed both the global index and local indices such as the S&P 500.
The largest positive contributor to fund performance was UCB, which rose by 39% on the back of very strong sales for Bimzelx – the first drug launched on the company’s new platform, targeting psoriasis as its initial indication. The company also has a promising pipeline with several potential product launches ahead.
The fund’s holding in biotechnology company Merus, focused on oncology – particularly brain tumors and potentially colorectal cancer – also performed strongly. The company received a takeover bid from Genmab at a 41% premium. Genmab, itself a fund holding, rose concurrently, further boosting returns.
Alnylam, which specializes in cardiovascular diseases, contributed positively as well. The substantial position in Thermo Fisher performed strongly, driven by positive demand prospects for laboratory equipment and new outsourcing contracts from pharmaceutical companies.
On the negative side, UnitedHealth Group, active in health insurance and hospital services, detracted from performance. The stock remains volatile, and the fund has now fully exited its position.
We are now more constructive on the sector as agreements are reached between the U.S. administration and major pharmaceutical companies. This creates greater clarity regarding future regulatory frameworks and business conditions. In our view, the valuation discount the sector has held relative to the broader market may begin to normalize over the next six months.
Portfolio distribution 30.09.2025
Geographic breakdown 30.09.2025
